Pyxis Oncology Inc
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candida… Read more
Pyxis Oncology Inc (PYXS) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.193x
Based on the latest financial reports, Pyxis Oncology Inc (PYXS) has a cash flow conversion efficiency ratio of -0.193x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.28 Million) by net assets ($68.78 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Pyxis Oncology Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how Pyxis Oncology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Pyxis Oncology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pyxis Oncology Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Genova Property Group AB
ST:GPG
|
0.008x |
|
Prospect Logistics and Industrial Leasehold Real Estate Investment Trust
BK:PROSPECT
|
0.015x |
|
Universal Cables Limited
NSE:UNIVCABLES
|
-0.002x |
|
Compagnie d Entreprises CFE SA
BR:CFEB
|
0.362x |
|
GEFRAN SPA EO 1
F:GF7
|
N/A |
|
DHP Korea Co. Ltd
KQ:131030
|
0.035x |
|
INKEVERSE GROUP DL-001
F:5IK
|
N/A |
|
Song Ba JSC
VN:SBA
|
N/A |
Annual Cash Flow Conversion Efficiency for Pyxis Oncology Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of Pyxis Oncology Inc from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $120.75 Million | $-57.67 Million | -0.478x | +15.09% |
| 2023-12-31 | $125.70 Million | $-70.71 Million | -0.563x | -1.26% |
| 2022-12-31 | $160.82 Million | $-89.33 Million | -0.555x | -310.90% |
| 2021-12-31 | $261.31 Million | $-35.33 Million | -0.135x | -120.97% |
| 2020-12-31 | $-15.64 Million | $-10.08 Million | 0.645x | -17.26% |
| 2019-12-31 | $-2.87 Million | $-2.24 Million | 0.779x | -- |